Elicio Therapeutics, Inc.

ELTX

Healthcare|Biotechnology|US

$1.51

+0.11 (+7.86%)

DCF Value

$0.23

Tangible Book / Share

$0.72

Cash / Share

$1.18

Next Earnings Report

Mar 11, 2027

EPS est. -$0.37

Financing Filings (last 12 months)

Shelf registrations / offering prospectuses — latest Jul 2, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (1)

Jun 2028

Est. completion

P1Pancreatic Cancer

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

NCT07671339n=20

Awaiting Results (1)

Trials past primary completion date but still active — data readout may be imminent.

Apr 2026

P1P2

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

NCT05726864

Recent Press Releases

Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Nov 5, 2026 · GlobeNewsWire

Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC

Nov 4, 2026 · GlobeNewsWire

Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting

Oct 29, 2026 · GlobeNewsWire

Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine

Oct 23, 2026 · GlobeNewsWire

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

Sep 24, 2026 · GlobeNewsWire

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Aug 31, 2026 · GlobeNewsWire

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

Aug 24, 2026 · GlobeNewsWire

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Aug 13, 2026 · GlobeNewsWire

SEC Filings (63)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

Filed	Form	What it is	Links
Nov 5, 2026	10-Q	Quarterly report	Document Index
Nov 5, 2026	8-K	Material event	Document Index
Oct 9, 2026	DEF 14A	Proxy / shareholder vote	Document Index
Sep 14, 2026	8-K	Material event	Document Index
Aug 13, 2026	10-Q	Quarterly report	Document Index
Aug 13, 2026	8-K	Material event	Document Index
Jul 16, 2026	SC 13G	Passive 5%+ stake	Document Index
Jul 8, 2026	SC 13G/A	Passive 5%+ stake	Document Index
Jul 2, 2026	424B5	Offering prospectus	Document Index
Jul 2, 2026	8-K	Material event	Document Index
Jun 24, 2026	8-K	Material event	Document Index
Jun 17, 2026	8-K	Material event	Document Index
Jun 15, 2026	8-K	Material event	Document Index
May 11, 2026	10-Q	Quarterly report	Document Index
May 11, 2026	8-K	Material event	Document Index
Apr 29, 2026	10-K/A	Annual report	Document Index
Mar 16, 2026	EFFECT		Document Index
Mar 16, 2026	8-K	Material event	Document Index
Mar 16, 2026	424B5	Offering prospectus	Document Index
Mar 12, 2026	S-8	Employee stock plan	Document Index
Mar 12, 2026	S-3/A	Shelf registration	Document Index
Mar 12, 2026	10-K	Annual report	Document Index
Mar 12, 2026	8-K	Material event	Document Index
Mar 2, 2026	S-3/A	Shelf registration	Document Index
Feb 27, 2026	S-3	Shelf registration	Document Index
Dec 3, 2025	EFFECT		Document Index
Nov 13, 2025	S-3	Shelf registration	Document Index
Nov 13, 2025	10-Q	Quarterly report	Document Index
Nov 13, 2025	8-K	Material event	Document Index
Oct 7, 2025	SC 13G/A	Passive 5%+ stake	Document Index
Sep 17, 2025	8-K	Material event	Document Index
Aug 12, 2025	8-K	Material event	Document Index
Aug 7, 2025	10-Q	Quarterly report	Document Index
Aug 7, 2025	8-K	Material event	Document Index
Aug 5, 2025	8-K	Material event	Document Index
Jun 4, 2025	SC 13D/A	Activist / 5%+ stake	Document Index
Jun 4, 2025	8-K	Material event	Document Index
May 20, 2025	8-K	Material event	Document Index
May 14, 2025	SC 13G/A	Passive 5%+ stake	Document Index
May 13, 2025	10-Q	Quarterly report	Document Index